Novel opioid antagonists for opioid-induced bowel dysfunction

Author： Diego Laura Atayee Rabia Helmons Pieter Hsiao Grace von Gunten Charles F

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.8, 2011-08, pp. : 1047-1056

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lubiprostone for the treatment of opioid-induced bowel dysfunction

By Wong Banny S Camilleri Michael

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 6, 2011-04 ,pp. : 983-990

Informa Healthcare

Access to resources Recommend Favorite

Opioid-Induced Bowel Dysfunction: Pathophysiology and Management

By Brock Christina > > Frøkjaer Jens Brøndum Andresen Trine >

Drugs, Vol. 72, Iss. 14, 2012-10 ,pp. : 1847-1865

Adis International

Access to resources Recommend Favorite

Opioid-Induced Bowel Dysfunction: Pathophysiology and Potential New Therapies

By Kurz A.

Drugs, Vol. 63, Iss. 7, 2003-01 ,pp. : 649-671

Adis International

Access to resources Recommend Favorite

Oxycodone/Naloxone in the Management of Patients with Pain and Opioid–Induced Bowel Dysfunction

Current Drug Targets, Vol. 15, Iss. 1, 2014-01 ,pp. : 124-135

Bentham Science Publishers

Access to resources Recommend Favorite

Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain

By Clemens Katri Elina Mikus Gerd

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 297-310

Informa Healthcare

Access to resources Recommend Favorite